Basilea Pharmaceutica AG (BSLN) — Long-term Investment Intensity
Basilea Pharmaceutica AG (BSLN) has a Long-term Investment Intensity of 13.5% as of December 2019. Long-term investments of CHF30.00 Million represent 13.5% of total assets of CHF221.47 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check Basilea Pharmaceutica AG liquidity resilience to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Basilea Pharmaceutica AG Long-term Investment Intensity (2016–2019)
This chart shows how Basilea Pharmaceutica AG's Long-term Investment Intensity has evolved across 3 annual periods from 2016 to 2019. As of December 2019, the intensity stands at 13.5%, reflecting long-term investments of CHF30.00 Million against total assets of CHF221.47 Million CHF. For the complete balance sheet picture, see BSLN total assets.
Annual Long-term Investment Intensity for Basilea Pharmaceutica AG (2016–2019)
The table below presents the year-by-year Long-term Investment Intensity for Basilea Pharmaceutica AG from 2016 to 2019, covering 3 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read how much debt does Basilea Pharmaceutica AG carry for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (CHF) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2019 | 13.5% | CHF30.00 Million | CHF221.47 Million | ▼ -0.7 pp |
| 2017 | 14.2% | CHF50.00 Million | CHF351.17 Million | ▼ -1.0 pp |
| 2016 | 15.3% | CHF50.00 Million | CHF327.76 Million | — |